Abiopharma

Financial Statements and Related Announcement: Full Yearly Results

New Form 6-K - SMITH & NEPHEW PLC Filed: 2025-08-28 AccNo: 0001654954-25-010114 Size: 29 KB

Nuvalent to Participate in the Cantor Global Healthcare Conference 2025

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™(bevacizumab-vikg) for the Treatment of Wet AMD

New Form 6-K - Apollomics Inc. Filed: 2025-08-28 AccNo: 0001193125-25-190310 Size: 123 KB

New Form 6-K - Haleon plc Filed: 2025-08-28 AccNo: 0001654954-25-010112 Size: 37 KB

New Form 8-K - ProPhase Labs, Inc. Filed: 2025-08-28 AccNo: 0001493152-25-012414 Size: 222 KB Item 1.02: Termination of a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits

New Form 6-K - GSK plc Filed: 2025-08-28 AccNo: 0001654954-25-010110 Size: 3 MB

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT, 2016

New Form EFFECT - IM Cannabis Corp. Filed: 2025-08-27 AccNo: 9999999995-25-002760 Size: 1 KB

New Form EFFECT - CARGO Therapeutics, Inc. Filed: 2025-08-27 AccNo: 9999999995-25-002752 Size: 1 KB

New Form EFFECT - CARGO Therapeutics, Inc. Filed: 2025-08-27 AccNo: 9999999995-25-002754 Size: 1 KB

Amphastar Pharmaceuticals to Present at the 2025 Wells Fargo Healthcare Conference

FDA approve CLINDAMYCIN PHOSPHATE

FDA approve DESMOPRESSIN ACETATE